Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom

• Status: Completed
• Trial end date: 2014-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study was to assess the effectiveness for small airway inflammation of 4 weeks lysozyme administration in Chronic Obstructive Pulmonary Disease (COPD) and/or asthma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eisai Co., Ltd.
• Treatments: Muramidase

Criteria

Inclusion criteria:

For COPD:

• Over 20 years of age and below 85 years of age

• Smoking history

• Brinkman index 200 or more

• Diagnosis of COPD

• Forced expiratory volume in 1 second (FEV1) of <80% of the predicted value

• Ratio of FEV1 to forced vital capacity (FVC) of <70%

• symptom of expectorated sputum

For Asthma

• Over 20 years of age and below 85 years of age

• Scored between 20 to 24 by ACT (Asthma Control Test)

• Symptom of expectorated sputum

• Diagnosed partly controlled by global initiative for asthma

Exclusion criteria:

• Egg allergy

• Domiciliary oxygen therapy

• Pneumonia or pulmonary tuberculosis

• Patients with severe cardiovascular disorder, severe kidney disorder, severe hepatic disorder, severe hematological disorder

• Cancer